Department of Ophthalmology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China,
Department of Ophthalmology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Ophthalmic Res. 2023;66(1):636-644. doi: 10.1159/000529342. Epub 2023 Feb 6.
The aim of the study was to report 2-year outcomes of intravitreal injection of high-dose conbercept (1 mg 2 + PRN scheme) for subjects with myopic choroidal neovascularization (mCNV) and idiopathic choroidal neovascularization (iCNV) by optical coherence tomography angiography follow-up.
A total of 38 subjects (38 eyes) were enrolled in this retrospective study, which were divided into group A (mCNV, 20 subjects, 20 eyes) and group B (iCNV, 18 subjects, 18 eyes). All subjects received 1.0 mg of conbercept intravitreally at diagnosis and again 35 days later. Additional conbercept injection was administered upon findings of decreased best-corrected visual acuity (BCVA); metamorphosis aggravation, macular hemorrhage, or edema; increased central retinal thickness (CRT); or leakage observed by fluorescein angiography. The BCVA, CRT, and CNV areas of the two groups were evaluated at baseline and at 1, 2, 4, 6, 12, and 24 months after surgery.
The BCVA of group A improved from 0.31 ± 0.16 logMAR at baseline to 0.12 ± 0.03 logMAR at the final follow-up (p < 0.001), while in group B the corresponding improvement was from 0.33 ± 0.16 logMAR at baseline to 0.12 ± 0.03 logMAR at the final follow-up (p < 0.001). Visual acuity improved in 17 subjects in group A and 15 in group B, while it remained stable in 3 subjects in each of groups A and B. CRT decreased from 311.83 ± 30.95 μm in group A and 351.17 ± 37.09 μm in group B preoperation to 229.56 ± 5.75 μm and 227.67 ± 4.98 μm at 24-month follow-up, respectively (p < 0.001 in groups A and B). Metamorphopsia was improved in subjects in groups A and B. CNV had disappeared in the two groups at the last postoperative visit. The BCVA, CRT, and CNV areas showed no statistical differences between the two groups at 6-, 12-, and 24-month follow-up (p > 0.05).
Intravitreal injection of conbercept (1 mg 2 + PRN scheme) is effective for treating patients with mCNV or iCNV, which can improve and stabilize vision as well as dramatically alleviate metamorphopsia.
本研究旨在通过光学相干断层扫描血管造影（OCTA）随访，报告高剂量康柏西普（1mg2+PRN 方案）治疗近视脉络膜新生血管（mCNV）和特发性脉络膜新生血管（iCNV）患者的 2 年结果。
本回顾性研究共纳入 38 名患者（38 只眼），分为 A 组（mCNV，20 名患者，20 只眼）和 B 组（iCNV，18 名患者，18 只眼）。所有患者在诊断时和 35 天后均接受了 1.0mg 的康柏西普玻璃体内注射。当发现最佳矫正视力（BCVA）下降、变形加重、黄斑出血或水肿、中央视网膜厚度（CRT）增加或荧光素血管造影显示渗漏时，会额外给予康柏西普注射。在手术前和手术后 1、2、4、6、12 和 24 个月评估两组的 BCVA、CRT 和 CNV 面积。
A 组的 BCVA 从基线时的 0.31±0.16logMAR 改善至最终随访时的 0.12±0.03logMAR（p<0.001），而 B 组的相应改善则从基线时的 0.33±0.16logMAR 改善至最终随访时的 0.12±0.03logMAR（p<0.001）。A 组有 17 名患者的视力提高，B 组有 15 名患者的视力提高，而 A、B 两组各有 3 名患者的视力保持稳定。A 组的 CRT 从术前的 311.83±30.95μm 降至 24 个月随访时的 229.56±5.75μm（p<0.001），B 组的 CRT 从术前的 351.17±37.09μm 降至 227.67±4.98μm（p<0.001）。A、B 两组的变形均得到改善。两组患者在末次随访时 CNV 均已消失。在 6、12 和 24 个月的随访中，两组的 BCVA、CRT 和 CNV 面积均无统计学差异（p>0.05）。
玻璃体内注射康柏西普（1mg2+PRN 方案）治疗 mCNV 或 iCNV 有效，可改善和稳定视力，并显著缓解变形。
